Dominik Stelzle1, Luana F Tanaka2, Kuan Ken Lee3, Ahmadaye Ibrahim Khalil4, Iacopo Baussano4, Anoop S V Shah5, David A McAllister6, Sami L Gottlieb7, Stefanie J Klug2, Andrea S Winkler8, Freddie Bray4, Rachel Baggaley9, Gary M Clifford4, Nathalie Broutet7, Shona Dalal10. 1. Center for Global Health, Department of Neurology, Faculty of Medicine, Technical University of Munich, Munich, Germany; Chair of Epidemiology, Department of Sport and Health Sciences, Technical University of Munich, Munich, Germany. 2. Chair of Epidemiology, Department of Sport and Health Sciences, Technical University of Munich, Munich, Germany. 3. British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK. 4. International Agency for Research on Cancer, Lyon, France. 5. Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. 6. Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK. 7. Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland. 8. Center for Global Health, Department of Neurology, Faculty of Medicine, Technical University of Munich, Munich, Germany; Centre for Global Health, Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway. 9. Department of Global HIV, Hepatitis and STIs Programmes, World Health Organization, Geneva, Switzerland. 10. Department of Global HIV, Hepatitis and STIs Programmes, World Health Organization, Geneva, Switzerland. Electronic address: dalals@who.int.
Abstract
BACKGROUND: HIV enhances human papillomavirus (HPV)-induced carcinogenesis. However, the contribution of HIV to cervical cancer burden at a population level has not been quantified. We aimed to investigate cervical cancer risk among women living with HIV and to estimate the global cervical cancer burden associated with HIV. METHODS: We did a systematic literature search and meta-analysis of five databases (PubMed, Embase, Global Health [CABI.org], Web of Science, and Global Index Medicus) to identify studies analysing the association between HIV infection and cervical cancer. We estimated the pooled risk of cervical cancer among women living with HIV across four continents (Africa, Asia, Europe, and North America). The risk ratio (RR) was combined with country-specific UNAIDS estimates of HIV prevalence and GLOBOCAN 2018 estimates of cervical cancer to calculate the proportion of women living with HIV among women with cervical cancer and population attributable fractions and age-standardised incidence rates (ASIRs) of HIV-attributable cervical cancer. FINDINGS: 24 studies met our inclusion criteria, which included 236 127 women living with HIV. The pooled risk of cervical cancer was increased in women living with HIV (RR 6·07, 95% CI 4·40-8·37). Globally, 5·8% (95% CI 4·6-7·3) of new cervical cancer cases in 2018 (33 000 new cases, 95% CI 26 000-42 000) were diagnosed in women living with HIV and 4·9% (95% CI 3·6-6·4) were attributable to HIV infection (28 000 new cases, 20 000-36 000). The most affected regions were southern Africa and eastern Africa. In southern Africa, 63·8% (95% CI 58·9-68·1) of women with cervical cancer (9200 new cases, 95% CI 8500-9800) were living with HIV, as were 27·4% (23·7-31·7) of women in eastern Africa (14 000 new cases, 12 000-17 000). ASIRs of HIV-attributable cervical cancer were more than 20 per 100 000 in six countries, all in southern Africa and eastern Africa. INTERPRETATION: Women living with HIV have a significantly increased risk of cervical cancer. HPV vaccination and cervical cancer screening for women living with HIV are especially important for countries in southern Africa and eastern Africa, where a substantial HIV-attributable cervical cancer burden has added to the existing cervical cancer burden. FUNDING: WHO, US Agency for International Development, and US President's Emergency Plan for AIDS Relief.
BACKGROUND:HIV enhances human papillomavirus (HPV)-induced carcinogenesis. However, the contribution of HIV to cervical cancer burden at a population level has not been quantified. We aimed to investigate cervical cancer risk among women living with HIV and to estimate the global cervical cancer burden associated with HIV. METHODS: We did a systematic literature search and meta-analysis of five databases (PubMed, Embase, Global Health [CABI.org], Web of Science, and Global Index Medicus) to identify studies analysing the association between HIV infection and cervical cancer. We estimated the pooled risk of cervical cancer among women living with HIV across four continents (Africa, Asia, Europe, and North America). The risk ratio (RR) was combined with country-specific UNAIDS estimates of HIV prevalence and GLOBOCAN 2018 estimates of cervical cancer to calculate the proportion of women living with HIV among women with cervical cancer and population attributable fractions and age-standardised incidence rates (ASIRs) of HIV-attributable cervical cancer. FINDINGS: 24 studies met our inclusion criteria, which included 236 127 women living with HIV. The pooled risk of cervical cancer was increased in women living with HIV (RR 6·07, 95% CI 4·40-8·37). Globally, 5·8% (95% CI 4·6-7·3) of new cervical cancer cases in 2018 (33 000 new cases, 95% CI 26 000-42 000) were diagnosed in women living with HIV and 4·9% (95% CI 3·6-6·4) were attributable to HIV infection (28 000 new cases, 20 000-36 000). The most affected regions were southern Africa and eastern Africa. In southern Africa, 63·8% (95% CI 58·9-68·1) of women with cervical cancer (9200 new cases, 95% CI 8500-9800) were living with HIV, as were 27·4% (23·7-31·7) of women in eastern Africa (14 000 new cases, 12 000-17 000). ASIRs of HIV-attributable cervical cancer were more than 20 per 100 000 in six countries, all in southern Africa and eastern Africa. INTERPRETATION:Women living with HIV have a significantly increased risk of cervical cancer. HPV vaccination and cervical cancer screening for women living with HIV are especially important for countries in southern Africa and eastern Africa, where a substantial HIV-attributable cervical cancer burden has added to the existing cervical cancer burden. FUNDING: WHO, US Agency for International Development, and US President's Emergency Plan for AIDS Relief.
Authors: Philip E Castle; Brian Befano; Mark Schiffman; Nicolas Wentzensen; Thomas Lorey; Nancy Poitras; Marianne Hyer; Li C Cheung Journal: Prev Med Date: 2022-07-08 Impact factor: 4.637
Authors: Cong Huang; Xiangmin Lv; Peichao Chen; Jiyuan Liu; Chunbo He; Li Chen; Hongbo Wang; Madelyn L Moness; Jixin Dong; Bo R Rueda; John S Davis; Cheng Wang Journal: Oncogene Date: 2022-06-27 Impact factor: 8.756
Authors: Venkatesan Chandran; M G Sumithra; Alagar Karthick; Tony George; M Deivakani; Balan Elakkiya; Umashankar Subramaniam; S Manoharan Journal: Biomed Res Int Date: 2021-05-04 Impact factor: 3.411
Authors: Aaron Ermel; Yan Tong; Phillip Tonui; Omenge Orang'o; Kapten Muthoka; Nelson Wong; Titus Manai; Stephen Kiptoo; Patrick J Loehrer; Darron R Brown Journal: Int J STD AIDS Date: 2021-07-07 Impact factor: 1.359
Authors: Michelle B Shin; Gui Liu; Nelly Mugo; Patricia J Garcia; Darcy W Rao; Cara J Bayer; Linda O Eckert; Leeya F Pinder; Judith N Wasserheit; Ruanne V Barnabas Journal: Front Public Health Date: 2021-07-01
Authors: H Rafferty; A S Sturt; C R Phiri; E L Webb; M Mudenda; J Mapani; P L A M Corstjens; G J van Dam; A Schaap; H Ayles; R J Hayes; L van Lieshout; I Hansingo; A L Bustinduy Journal: BMC Infect Dis Date: 2021-07-17 Impact factor: 3.090